PhoenixLights
Posted - 42 minutes ago
$IBRX. Somehow, I missed this AUA PSS Anktiva chat with Dr. Sam Chang at the AUA conference. Wow!!! Just absolutely, WOW!!! https://immunitybio.com/dr-patrick-soon-shiong-discusses-anktiva-with-dr-sam-chang-at-recent-aua-conference/
TomMac64
Posted - 1 hour ago
$IBRX Remember this day ? next day they hit a bunch of stop losses and we hit $3.50 ? Two things one no stop losses with this stock and 2 make sure you have chalk at all times it wasn’t $3.50 for very long .
TomMac64
Posted - 1 hour ago
$IBRX If you look at the chart below much of those periodic bullish spikes have taken place “just because it’s IBRX” and XBI !
tjguy
Posted - 1 hour ago
Can someone summarize the catalysts for the next couple of months please? I am sure I am missing some, but here is what I have: 1) Meeting with the FDA in June about using Anktiva with Lung cancer. But what exactly will the FDA be deciding on? 2) Release of BCG Naïve trial results 3) European approval of Anktiva or something to do with their label? 4) FDA should be greenlighting the use of Serum Institute’s BCG drug for usage in a Phase 2 trial to prove this new type of BCG is safe. 5) Q2 results in August $IBRX
TomMac64
Posted - 1 hour ago
$IBRX yes ! and that’s why this chart will repeat over the next 6 month just ride the volatility !
Blarcamesine
Posted - 1 hour ago
$IBRX just need a sales update. Sales began in May..
BullriderNkg
Posted - 1 hour ago
$IBRX Are the following statements close to accurate? 691 Mil out standing shares.
70 Mil Institutionally held shares. PSS entities 83% closely held = 573 Mil. That leaves 48 Mil in retail hands. Some hodlrs and some flippers. 50+ Mil Short. Where have I errored?
Even without a squeeze, someone in the above 3 groups must sell for Shorts to close out. Naked shorting only compounds and makes this more baffeling to me, unless they cover daily. COMMENTS, GUIDANCE ANYONE???
Musky49
Posted - 1 hour ago
$IBRX Recombinant BCG is the future in my opinion ⬆️CD8+/CD4’s
A cytotoxic T cell, also known as a killer T cell or CD8+ T-cell, is a type of white blood cell that plays a crucial role in the immune system. These cells recognize and destroy cancer cells, cells infected by intracellular pathogens (such as viruses or bacteria), or damaged cells1. CD8 cells are considered “killers” because their function is to eliminate cells harboring viruses, bacteria, or other disease-causing agents. They work alongside CD4 T cells, which are considered “helpers” and initiate immune responses
TheWinningStock
Posted - 1 hour ago
$IBRX <<-- ChatGPT things that IBRX is in the cutting edge of cancer therapies.. We need to keep buying and hold, just my opinion, this is a safe investment, I just exercised 10 option contracts at $7.5 yesterday.
BigFella2021
Posted - 1 hour ago
$IBRX a very good post that points to the power that the friggin bastard piece of shit hedge funds and market makers have. As much as it angers me, the average retail investor just has to be patient and await what the big boys do. They are playing 5 card draw poker, and have 5 cards, retailers are playing against them, and we have 1 card. Go IBRX and go PSS!!!
Silent_But_Deadly_Turd
Posted - 3 hours ago
$IBRX we needs an update on ass cancer
huggenberg
Posted - 3 hours ago
$IBRX Let’s talk about prostate cancer. During the AUA fireside chat on May 3rd, PSS announced a new Phase II trial in collaboration with the NCI. This trial design will be an adoptive cell therapy with autologous cells and activating the cells with Adeno-PSA. This involves extracting immune cells from the patient, growing them, and treating them with an Adeno-PSA vaccine meant to enhance their activity, reinserting the cells in the patient’s body. This contrasts the PI trial from 2021, where ETBX-071 was subcutaneously injected. I haven’t found any trials yet on the clinical trials site.
day_um
Posted - 3 hours ago
$IBRX
Silent_But_Deadly_Turd
Posted - 4 hours ago
$IBRX morning
mrsmrs
Posted - 5 hours ago
$IBRX why are some people expecting a PR?
deporte1800
Posted - 7 hours ago
$IBRX Very interesting... Let everyone do their own math at home... Institutional shareholders yesterday stood at 70.5m out of 150m = float. Information extracted from Fintel. The number of shares held by shorts is 55,000,000 shares. How many shares are held by minority shareholders? ....... What are the shorts going to do to cover their positions, can someone explain it to me?
HeyU2001
Posted - 8 hours ago
$IBRX Anyone one aware of an email or test alarm notification? I am on the road the next couple weeks and would like to have an email or a text if price hits different numbers.
Headhunter80904
Posted - 9 hours ago
@Teachamantofish @Bigger_E @deporte1800 @FlipStink $IBRX I do agree with you there are many scenarios, and posted that to demonstrate that it’s much more complex than a straightforward short squeeze than most realize. Also, that the shorts and MMs can sometimes be working in concert, sometimes in opposition, even if they’re both from Citadel.
Headhunter80904
Posted - 9 hours ago
@Teachamantofish @FlipStink @Bigger_E @deporte1800 $IBRX Seems to me like you fit the hypothesis, though with some serious size. 🫡 You’re going to be unloading ~150,000 shares tomorrow (along with many other assignees), and it remains MHO that MMs will be building inventory looking ahead to 6/21, for which they already need ~4.3 million shares to cover the calls up to $12.5
Musky49
Posted - 10 hours ago
$IBRX Key word - complete. “The collaboration between Serum Institute of India and ImmunityBio will undoubtedly transform the way we approach cancer treatment. It will improve global access to BCG and at the same time—the unique therapy is the key to achieve a complete solution for bladder cancer. We are truly excited to witness the incredible impact this collaboration will have on improving patient outcomes and saving countless lives,” said Mr. Adar C. Poonawalla, CEO, Serum Institute of India.
ACES_
Posted - 10 hours ago
$IBRX CHESS... NOT CHECKERS... Love this guy... gonna be huge.. https://x.com/DrPatSoonShiong/status/1791592716046131296
Silent_But_Deadly_Turd
Posted - 10 hours ago
$IBRX feels like the board half ass knows the facts
SA1978
Posted - 11 hours ago
$IBRX Connecting the dots… stay tuned.
BillNichelle
Posted - 11 hours ago
$IBRX notice how there's no negativity in the board during the weekend? Only when the stock Dips a few cents is the only thing bears can bash this company about. Beautiful.
Biofrog
Posted - 11 hours ago
$IBRX Very interesting discussion for a saturday nite. Loving it.
PatSoonDiggler
Posted - 11 hours ago
$EVGO $IBRX $LOCO !!!!!!!
“In 2021 alone, over 134,500 died of lung cancer in the U.S. If 50% of those patients had been treated with Anktiva and the drug cost $50,000 annually, ImmunityBio would have received $3.36 billion of revenue that year.
Given Anktiva’s effectiveness, along with the possibility that it could potentially treat other types of cancers, the drug maker’s market capitalization of $5.6 billion is far too low.”
runflat
Posted - 11 hours ago
$IBRX Gonna be a great week, feel it in my bones. I feel like a million bucks (pre Biden)
